MY008211A is named as an intervention in 4 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Wuhan Createrna Science and Technology Co., Ltd. The most-studied condition is Paroxysmal Nocturnal Hemoglobinuria (PNH).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
NCT06932471 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria
|
Phase 3 | Recruiting | Wuhan Createrna Science and Technology Co., Ltd | China |
|
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
NCT06932744 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Haemoglobinuria (PNH)
|
Phase 3 | Recruiting | Wuhan Createrna Science and Technology Co., Ltd | China |
|
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06933914 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2/3 | Recruiting | Wuhan Createrna Science and Technology Co., Ltd | China |
|
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
NCT06687174 · ClinicalTrials.gov ↗ · IgA Nephropathy (IgAN)
|
Phase 2 | Not yet open | Wuhan Createrna Science and Technology Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Wuhan Createrna Science and Technology Co., Ltd | 4 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 3 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name MY008211A as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 4 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Wuhan Createrna Science and Technology Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how MY008211A works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MY008211A works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MY008211A (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.